Skin and Joints Podcast

PART 2: PsO and the Art of Decision Making with Dr.Maxwell Sauder

Episode Summary

🎙️✨ Dive into Part 2 of the Skin and Joints Podcast with Dr.Max Sauder: PsO and the Art of Decision Making with Dr.Maxwell Sauder where we delve into the groundbreaking reSURFACE 1 and reSURFACE 2 Trials on Tildrakizumab in PsO exploring the Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 weeks. Dr. Sauder takes us through a deep dive into the study's findings, highlighting the similar improvement rates in skin lesions and disease-related quality of life among younger and older patients alike. PART 2 explores: The Dr.Sauder Method: why this treatment stands out in Dr. Sauder's arsenal against psoriasis, not just for the elderly but across all ages and how he makes real world decisions in clinic From a mechanistic perspective, do we have an idea as to what is going on? As a form of precision medicine, we also explore a study that aimed to investigate the specific patient population that would derive the greatest benefit from tildrakizumab, as well as the mechanism of action and efficacy of tildrakizumab in reducing the occurrence of psoriatic arthritis (PsA). This study also examined the quantity and role of regulatory T cells (Tregs) and T helper 17 cells both pre- and post-treatment-what do you need to know? Episode supported by an IME Grant from SUN Pharma About Dr.Maxwell Sauder MD, FRCPC Dermatologist  | Toronto Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School. Dr. Sauder is currently an assistant professor at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he is the research director and the director of the Pigmented Lesion Clinic. Well published in numerous peer-reviewed journals, Dr. Sauder has also authored several book chapters, been referenced on www.uptodate.com, and has won numerous awards including the Partner’s President Prize at Harvard and the Royal College’s Detweiler Fellowship Award. His publications have covered topics such as eczema, patient education, aesthetic dermatology, sun safety, psoriasis, biologics, adverse drug reactions, hemangiomas, contact dermatitis, cutaneous oncology, and a host of complex medical dermatology conditions. 📻www.skinandjoints.ca ✉️info@skinandjoints.ca

Episode Notes

🎙️✨ Dive into Part 2 of the Skin and Joints Podcast with Dr.Max Sauder: PsO and the Art of Decision Making with Dr.Maxwell Sauder  where we delve into the groundbreaking reSURFACE 1 and reSURFACE 2 Trials on Tildrakizumab in PsO exploring the Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 weeks.

Dr. Sauder takes us through a deep dive into the study's findings, highlighting the similar improvement rates in skin lesions and disease-related quality of life among younger and older patients alike.

PART 2 explores:

• The Dr.Sauder Method: why this treatment stands out in Dr. Sauder's arsenal against psoriasis, not just for the elderly but across all ages and how he makes real world decisions in clinic 
• From a mechanistic perspective, do we have an idea as to what is going on? As a form of precision medicine, we also explore a study that aimed to investigate the specific patient population that would derive the greatest benefit from tildrakizumab, as well as the mechanism of action and efficacy of tildrakizumab in reducing the occurrence of psoriatic arthritis (PsA).
• This study also examined the quantity and role of regulatory T cells (Tregs) and T helper 17 cells both pre- and post-treatment-what do you need to know?

Episode supported by an IME Grant from SUN Pharma
 

About Dr.Maxwell Sauder MD, FRCPC

Dermatologist  |  Toronto 

Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School.

Dr. Sauder is currently an assistant professor at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he is the research director and the director of the Pigmented Lesion Clinic.

Well published in numerous peer-reviewed journals, Dr. Sauder has also authored several book chapters, been referenced on www.uptodate.com, and has won numerous awards including the Partner’s President Prize at Harvard and the Royal College’s Detweiler Fellowship Award. His publications have covered topics such as eczema, patient education, aesthetic dermatology, sun safety, psoriasis, biologics, adverse drug reactions, hemangiomas, contact dermatitis, cutaneous oncology, and a host of complex medical dermatology conditions. 

📻www.skinandjoints.ca

✉️info@skinandjoints.ca